Among 527 incident patients starting incremental peritoneal dialysis, 64% remained on the same starting prescription at one year and 36% had not incremented by two years. Younger age, male sex, and lower albumin predicted earlier escalation. Transfers to haemodialysis were mainly associated with lifestyle, fluid overload, uraemic symptoms, younger age, diabetes, lower albumin, and lower starting eGFR. Mortality was low, but the proposed score needs external validation.

Clinical impact: Supports individualized incremental-PD discussions when residual kidney function and clinical status permit; it is observational evidence, not proof that incremental PD is universally safe.

Clinical relevance: High
View original article →

In matched adults starting in-centre haemodialysis, GLP-1 receptor agonist use in the first month was associated with lower hospitalization rates (IRR 0.91; 95% CI 0.87–0.96) and mortality rates (IRR 0.83; 95% CI 0.73–0.95). The cohort was predominantly diabetic and observational, so residual confounding and treatment-selection bias remain possible.

Clinical impact: Encouraging real-world signal for GLP-1 receptor agonists in selected patients with ESKD, but treatment decisions should follow approved indications, tolerability, and individualized metabolic assessment.

Clinical relevance: Moderate
View original article →

Across 2,727 people with eGFR 15–45 mL/min/1.73 m², higher urine protein-to-creatinine ratios strongly predicted CKD progression. Compared with <0.5 g/g, time-updated ratios of 0.5–1.0, 1.0–3.0, and ≥3.0 g/g were associated with hazard ratios of 2.58, 5.61, and 12.88, respectively. Higher proteinuria also corresponded to faster eGFR decline and shorter projected time to eGFR 10.

Clinical impact: Reinforces proteinuria as a powerful prognostic marker in advanced CKD and supports repeated quantitative assessment alongside eGFR and treatment response.

Clinical relevance: High
View original article →

In 85 hemodynamically stable patients with dialysis-requiring AKI, measured creatinine clearance discriminated near-term dialysis need better than urine output. Dialysis was not required during the following week in 81% of collections with clearance 10–20 mL/min and 44% with clearance 5–<10 mL/min. The analysis used protocolized indications and blinded timed collections.

Clinical impact: Supports using timed clearance and clinical indications when assessing dialysis liberation; results should not be applied without attention to haemodynamic stability, volume, electrolytes, and uraemic complications.

Clinical relevance: High
View original article →

A KDIGO Asia-Pacific summit identified barriers to implementing diabetes and blood-pressure guidance in CKD across 13 countries or regions. Priorities included lifestyle support, integrated team-based care, albuminuria screening, and access to guideline-directed therapies. The report proposes actions tailored to local income level and health-system capacity rather than a single universal implementation model.

Clinical impact: Useful systems-level framework for adapting CKD care pathways; it is a consensus/implementation report, not comparative outcome evidence.

Clinical relevance: Moderate
View original article →

An international expert forum reviewed the emerging role of complement inhibition in C3G, immune-complex MPGN, and IgA nephropathy. The report emphasizes uncertainty around patient selection, complement biomarkers, autoantibodies, genetics, biopsy findings, and how new inhibitors should fit within existing therapy. It outlines priorities for real-world use and future research.

Clinical impact: Helpful for framing complement-targeted treatment decisions, but forum recommendations should not be interpreted as a substitute for approved indications or trial-level evidence.

Clinical relevance: Moderate
View original article →

Among 1,551 patients with sepsis, new AKI occurred in 44.8%. A high-risk immune endotype combined immunoglobulin A, procalcitonin, complement C3 depletion, and altered CD4-positive T-cell patterns. An XGBoost model integrating immune and routine clinical variables achieved an AUC of 0.914 versus 0.788 for the clinical model. External validation and impact testing remain necessary.

Clinical impact: Promising early-risk stratification research, but the model is not ready to guide bedside decisions without independent validation and calibration.

Clinical relevance: Moderate
View original article →

In 72 biopsy-confirmed cases, bortezomib/dexamethasone produced higher hematologic and renal response rates than thalidomide/dexamethasone and was associated with better five-year renal survival (73% versus 51%). Neurotoxicity was less frequent with bortezomib than thalidomide. Eight transplant-eligible patients had deeper hematologic responses after autologous stem-cell transplantation. Confounding by treatment selection remains possible.

Clinical impact: Supports bortezomib-based plasma-cell therapy as an important regimen to discuss with haematology, while recognizing the retrospective design and need for individualized toxicity assessment.

Clinical relevance: High
View original article →

This review recommends risk-adapted rather than fixed HLA-antibody monitoring in pediatric kidney recipients. It highlights prolonged allograft exposure, adolescence-related nonadherence, immunosuppressive regimen, and prior immunologic risk as reasons to individualize testing intervals and trigger-based reassessment. Mean fluorescence intensity should be interpreted in clinical context rather than used as an isolated decision threshold.

Clinical impact: Provides a practical framework for pediatric transplant surveillance, but monitoring schedules should follow local protocols and multidisciplinary interpretation.

Clinical relevance: High
View original article →

Among 43 of 60 US pediatric PD centers responding, 83% had a flushing protocol and 98% routinely flushed catheters, but timing, solution, volume, heparin use, and management of bloody effluent varied substantially. Weekly flushing was common and 10 mL/kg was a typical volume. The survey demonstrates practice variation rather than comparative effectiveness.

Clinical impact: Highlights an actionable standardization gap in pediatric PD; prospective multicenter studies are needed before one flushing protocol is adopted broadly.

Clinical relevance: Moderate
View original article →

Across 3,070 kidney transplant recipients, belatacept was not associated with a statistically significant difference in skin cancer or overall cancer compared with calcineurin-inhibitor regimens. Conversion from calcineurin inhibitors showed a non-significant trend toward higher cancer risk than de novo belatacept. The evidence is limited by event numbers, heterogeneity, and cancer outcomes not being primary endpoints.

Clinical impact: Reassuring but not definitive safety evidence; cancer screening and immunosuppression decisions should remain individualized.

Clinical relevance: Moderate
View original article →

This verified Kidney360 record addresses access to preemptive waitlisting among prior living kidney donors who later develop ESKD. PubMed did not provide an abstract at review time, so this entry is limited to the verified title and publication record; no unverified numerical findings are inferred.

Clinical impact: Potentially important for donor follow-up and transplant access policy, but readers should consult the full article before drawing clinical conclusions.

Clinical relevance: Moderate
View original article →